Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 10, 2017British Journal of DermatologyOpen Access

Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAndrew BlauveltUniversity of GenevaLFLaura K. FerrisUniversity of North Carolina at Chapel HillPYPaul S. YamauchiUniversity of California, Los Angeles

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Blauvelt et al. (2017) studied this question.

synapsesocial.com/papers/6aa717ba4bfde8663e6df953https://doi.org/10.1111/bjd.15722
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up2014 · 206 citations
  2. 2Severe Psoriasis – Oral Therapy with a New Retinoid2009 · 2,750 citations
  3. 3Statistics Notes: Diagnostic tests 2: predictive values1994 · 1,739 citations
  4. 4Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis2008 · 213 citations
  5. 5A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis2007 · 809 citations